[Pharmacological study on kasugamycin].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D002415:Cats; D004285:Dogs; D004355:Drug Stability; D004386:Duodenum / Q000187:drug effects; D004562:Electrocardiography; D004576:Electromyography; D005260:Female; D006168:Guinea Pigs; D006863:Hydrogen-Ion Concentration; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007583:Jejunum / Q000187:drug effects; D008297:Male; D051379:Mice; D009130:Muscle, Smooth / Q000187:drug effects; D010996:Pleural Effusion / Q000032:analysis; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012867:Skin / Q000187:drug effects; D012995:Solubility; D013302:Streptomyces
D000900:Anti-Bacterial Agents